Aims Adalimumab is a biological therapy used to treat different chronic inflammatory
diseases. At present, there is an increasing number of adalimumab biosimilars. To assume …

Biosimilar medicines support the sustainability of national healthcare systems, by reducing
costs of biological therapies through increased competition. However, their adoption into …

As the patents for biologic originator drugs expire, biosimilars are emerging as cost-effective
alternatives within healthcare systems. Addressing various challenges in the clinical …

Although patient acceptance is important for biosimilar adoption and reducing healthcare
costs, many patients perceive biosimilars to be unsafe and have concerns about switching …

Objective To systematically summarize and evaluate the findings of existing studies about
patients' perceptions of biosimilars by assessing their attitudes and knowledge. Methods We …

Several efforts have been made to improve the available therapeutic armamentarium of
patients with immune-mediated inflammatory disorders (IMIDs) leading to the development …

Introduction The use of biosimilars for the treatment of patients with chronic inflammatory
bowel diseases (IBD) showed to be a valid strategy to reduce the economic burden of …

Background: Subcutaneous infliximab and vedolizumab formulations have been developed
for maintenance therapy in inflammatory bowel disease. The objective of this study was to …

Effective patient-provider communication is crucial to promote shared decision-making.
However, it is unclear how to explain treatment changes to ensure patient acceptance, such …

Background: By improving the affordability and accessibility of biologicals, biosimilar
competition provides important benefits to healthcare systems and patients. In Belgium …